Lusvertikimab & the Future of IBD: KOL Insights Post-ECCO

Save the date and join OSE Immunotherapeutics on 5 March at 6pm CET | 12pm ET for an exclusive webinar featuring top key opinion leaders (KOLs) and industry experts on the latest scientific and clinical highlights from ECCO 2025, with a focus on lusvertikimab (OSE-127) and advancements in the treatment of inflammatory bowel disease (IBD).

The webinar, presented by OSE Immunotherapeutics, aims to share key scientific and clinical highlights from ECCO 2025, focusing on the latest trends and high-level insights. We will present the most recent clinical trial results, with a focus on the positive results of lusvertikimab in ulcerative colitis (UC), and other scientific data, highlighting the significance of these findings in the current research and therapeutic landscape. Additionally, we will explain how these advancements address unmet patient needs and their potential impact on patient care. The webinar will also provide a high-level overview of the current therapeutic landscape in IBD, with a deeper dive into UC.

The event will feature:

• Professor Laurent Peyrin-Biroulet, Nancy University Hospital, France, who will discuss the current treatment landscape in UC.
• Nicolas Poirier, CEO of OSE Immunotherapeutics, who will provide an overview of the company’s lead immuno-inflammation asset, lusvertikimab.
• Professor Arnaud Bourreille, CHU Nantes, France, who will introduce the data presented at ECCO from the Phase II CoTiKiS trial.
• Professor Vipul Jairath, Schulich School of Medicine & Dentistry, Ontario, Canada, who will share further insights into the implications of the latest data.
• Arron Aatkar, healthcare analyst at Edison Group, who will chair the panel and Q&A session.

About OSE Immunotherapeutics:

OSE Immunotherapeutics (PAR: OSE) is a leading biotech company committed to pioneering breakthroughs in immuno-oncology and immuno-inflammation. Its lead immuno-inflammation asset is lusvertikimab (formerly OSE-127), an antibody therapy acting as an IL-7R antagonist, which is in clinical development as a potential treatment for ulcerative colitis. It recently completed a Phase II trial (CoTiKiS), which met its primary endpoint with statistical significance. OSE’s R&D pipeline is robust and diverse, comprising both proprietary and partnered programmes, ensuring that its progress remains resilient and independent of any singular subsector.